Cladribine tablets and multiple sclerosis: NICE technology appraisal

被引：0
|
作者：
Gaber, Tarek [1 ]
Shippen, Clare [2 ]
机构：
[1] Wrightington Wigan & Leigh NHS Fdn Trust, Neurol Rehabil, Wigan, England
[2] North West Deanery, Rehabil Med, Manchester, Lancs, England
来源：
PROGRESS IN NEUROLOGY AND PSYCHIATRY | 2018年 / 22卷 / 01期
关键词：
D O I：
10.1002/pnp.486
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Cladribine is the first disease modifying treatment (DMT) for relapsing remitting multiple sclerosis (RRMS) that progressed straight to a positive final recommendation in the NICE appraisal process. The final recommendations were published in December 2017.(1) An agreement between NHS England and Merck, the manufacturer of cladribine (Mavenclad), will allow MS patients who are suffering from highly active or rapidly evolving RRMS to access the drug. Here, the authors discuss the clinical and economic considerations for cladribine usage.
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [1] Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Tosin Lambe
    Rui Duarte
    James Mahon
    Sarah Nevitt
    Janette Greenhalgh
    Angela Boland
    Sophie Beale
    Eleanor Kotas
    Joanne McEntee
    Ian Pomeroy
    PharmacoEconomics, 2019, 37 : 345 - 357
  • [2] Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Lambe, Tosin
    Duarte, Rui
    Mahon, James
    Nevitt, Sarah
    Greenhalgh, Janette
    Boland, Angela
    Beale, Sophie
    Kotas, Eleanor
    McEntee, Joanne
    Pomeroy, Ian
    PHARMACOECONOMICS, 2019, 37 (03) : 345 - 357
  • [3] Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Hamlett, A.
    Miret, M.
    Weiner, J.
    Viglietta, V.
    Musch, B.
    Greenberg, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (05) : 578 - 593
  • [4] Cladribine Tablets' Potential in Multiple Sclerosis Treatment
    Costello, Kathleen
    Sipe, Jack C.
    JOURNAL OF NEUROSCIENCE NURSING, 2008, 40 (05) : 275 - 280
  • [5] Recommendations for the use of cladribine tablets in recurring multiple sclerosis
    Oreja-Guevara, Celia
    Garcia-Merino, Juan A.
    Saiz, Albert
    Rodriguez-Antiguedad, Alfredo
    Alvarez-Cermeno, Jose C.
    Estrada-Perez, Vicente
    Izquierdo, Guillermo
    Fernandez, Oscar
    REVISTA DE NEUROLOGIA, 2019, 69 : S1 - S9
  • [6] Cladribine Tablets In Relapsing-Remitting Multiple Sclerosis
    Muir, Victoria J.
    Plosker, Greg L.
    CNS DRUGS, 2011, 25 (03) : 239 - 249
  • [7] The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
    Rammohan, Kottil
    Coyle, Patricia K.
    Sylvester, Elke
    Galazka, Andrew
    Dangond, Fernando
    Grosso, Megan
    Leist, Thomas P.
    DRUGS, 2020, 80 (18) : 1901 - 1928
  • [8] MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study
    Comi, Giancarlo
    Cook, Stuart D.
    Giovannoni, Gavin
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Hamlett, Anthony C.
    Viglietta, Vissia
    Greenberg, Steven J.
    JOURNAL OF NEUROLOGY, 2013, 260 (04) : 1136 - 1146
  • [9] Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis
    Victoria J. Muir
    Greg L. Plosker
    CNS Drugs, 2020, 34 : 447 - 447
  • [10] Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kurukulasuriya, Nuwan C.
    Greenberg, Steven J.
    Scaramozza, Matthew
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 123 - 136
12345